Report cover image

Interleukin 1 beta inhibitors - Pipeline Insight, 2025

Publisher DelveInsight
Published Apr 01, 2025
Length 60 Pages
SKU # DEL19993673

Description

DelveInsight’s, “Interleukin 1 Beta Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 11+ companies and 12+ pipeline drugs in Interleukin 1 Beta Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Interleukin 1 Beta Inhibitors Understanding

Interleukin 1 Beta Inhibitors: Overview

Interleukin 1 Beta Inhibitors is a potent pro-inflammatory cytokine produced by cells of the innate immune system. Interleukin 1 beta (IL-1β) is produced as an inactive 31 kDa precursor, termed pro-IL-1β, in response to molecular motifs carried by pathogens called ‘pathogen associated molecular patterns’ (PAMPs). It is a major cytokine involved in monocyte activation and activation of proinflammatory signaling pathways in peripheral tissues and brain. IL-1β expression and its secretion are tightly regulated. IL-1β is a master regulator of inflammation via controlling a variety of innate immune processes. IL-1 has a wide range of biological functions, which include acting as a leukocytic pyrogen, a mediator of fever and a leukocytic endogenous mediator, and an inducer of several components of the acute-phase response and lymphocyte-activating factor (LAF). The blocking of IL-1 could be effective strategies for the management of classic autoimmune diseases and autoinflammatory diseases.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin 1 Beta Inhibitors R&D. The therapies under development are focused on novel approaches for Interleukin 1 Beta Inhibitors.
Interleukin 1 Beta Inhibitors Emerging Drugs Chapters

This segment of the Interleukin 1 Beta Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interleukin 1 Beta Inhibitors Emerging Drugs
  • Gevokizumab: Novartis
Gevokizumab (VPM087) is a novel, human-engineered monoclonal anti - IL-1β antibody. Gevokizumab binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine. The drug is in Phase I clinical studies for the treatment of patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.
  • Goflikicept: TRPHARM
Goflikicept (RPH-104) is a heterodimeric fusion protein containing IL-1R1 and IL-1RAcP linked to immunoglobulin heavy chains and is highly selectively binds IL-1β. TRPHARM is evaluating Goflikicept in Phase II/III clinical studies for the treatment of Pericarditis and in Phase II clinical studies for Gout Attack and myocardial infarction.

Further product details are provided in the report……..

Interleukin 1 Beta Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Interleukin 1 Beta Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Interleukin 1 Beta Inhibitors
There are approx. 11+ key companies which are developing the Interleukin 1 Beta Inhibitors. The companies which have their Interleukin 1 Beta Inhibitors drug candidates in the most advanced stage, i.e. Phase II/III include, TRPHARM.
  • Phases
DelveInsight’s report covers around 12+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Interleukin 1 Beta Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interleukin 1 Beta Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin 1 Beta Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin 1 Beta Inhibitors drugs.

Interleukin 1 Beta Inhibitors Report Insights
  • Interleukin 1 Beta Inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Interleukin 1 Beta Inhibitors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Interleukin 1 Beta Inhibitors drugs?
  • How many Interleukin 1 Beta Inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Interleukin 1 Beta Inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin 1 Beta Inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Interleukin 1 Beta Inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Novartis
  • Regeneron Pharmaceuticals
  • TRPHARM
  • Hutchison MediPharma
  • Tetra Bio Pharma
  • Jiangsu T-mab BioPharma
  • Flame Biosciences
Key Products
  • Canakinumab
  • Rilonacept
  • Gevokizumab
  • Goflikicept
  • HMPL-004
  • HU 308
  • TK 002
  • FL-101 Flame Biosciences

Table of Contents

60 Pages
Introduction
Executive Summary
Interleukin 1 Beta Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Interleukin 1 Beta Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Interleukin 1 Beta Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Interleukin 1 Beta Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Goflikicept: TRPHARM
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Gevokizumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
FL-101: Flame Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interleukin 1 Beta Inhibitors Key Companies
Interleukin 1 Beta Inhibitors Key Products
Interleukin 1 Beta Inhibitors- Unmet Needs
Interleukin 1 Beta Inhibitors- Market Drivers and Barriers
Interleukin 1 Beta Inhibitors- Future Perspectives and Conclusion
Interleukin 1 Beta Inhibitors Analyst Views
Interleukin 1 Beta Inhibitors Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us